{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:08:18Z","timestamp":1791432498224,"version":"4.3.3"},"reference-count":49,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder characterized by progressive muscle weakness leading to permanent disability. There are no curative treatments, however, there are several upcoming clinical trials testing new therapies in FSHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to explore the disease burden and patient preferences of people with FSHD to ensure that clinical trials can be designed to include outcome measures that are relevant and important to patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A survey was developed with a steering committee clinicians and physiotherapists with relevant experience in the disease, patient representatives, a registry expert and industry consultants. Themes of the survey included; participant demographics, disease progression and impact on function, factors encouraging or discouraging clinical trial participation, and positive outcomes of a clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>1147 participants responded to the online survey, representing 26 countries across Europe and a range of disease severities. The study highlighted the key symptoms causing concern for FSHD patients - muscle weakness and mobility issues - reflecting what participants want targeted for future therapies. The need for clear information and communication throughout clinical trials was emphasised. Factors most encouraging trial participation included access to new investigational therapies, access to trial results and benefits for the FSHD community. Factors most discouraging trial participation included travel related issues and fear of side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The results from this study identify the patient reported burden of FSHD and should provide researchers and industry with areas of therapeutic research that would be meaningful to patients, as well as supporting the development of patient centric outcome measures in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jnd-230171","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T12:18:24Z","timestamp":1706271504000},"page":"459-472","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation"],"prefix":"10.1177","volume":"11","author":[{"given":"Megan M.","family":"McNiff","sequence":"first","affiliation":[{"name":"John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Hawkins","sequence":"additional","affiliation":[{"name":"FSHD Europe, Radboud University Medical Centre, Department of Neurology, HB Nijmegen, TheNetherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bine","family":"Haase","sequence":"additional","affiliation":[{"name":"FSHD Europe, Radboud University Medical Centre, Department of Neurology, HB Nijmegen, TheNetherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Bullivant","sequence":"additional","affiliation":[{"name":"John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"McIver","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, PD Data Sciences, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mitelman","sequence":"additional","affiliation":[{"name":"Fulcrum Therapeutics, Inc., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Emery","sequence":"additional","affiliation":[{"name":"The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Tasca","sequence":"additional","affiliation":[{"name":"John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"Unit\u00e0 Operativa Complessa di Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol","family":"Voermans","sequence":"additional","affiliation":[{"name":"FSHD Europe, Radboud University Medical Centre, Department of Neurology, HB Nijmegen, TheNetherlands"},{"name":"Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Diaz-Manera","sequence":"additional","affiliation":[{"name":"John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.01.001"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000797"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0960-x"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrleng.2015.02.006"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02100-z"},{"key":"ref006","doi-asserted-by":"crossref","unstructured":"Jeffrey Statland RT Facioscapulohumeral Muscular Dystrophy. Neurologic Clinics. 2014;32.","DOI":"10.1016\/j.ncl.2014.04.003"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-016-0667-0"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000399"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200554"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.1.46"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.8.1434"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21338"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2008.12.027"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0616-9"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00482-z"},{"key":"ref016","unstructured":"Medical Device Innovation Consortium, Medical Device Innovation Consortium (MDIC) Patient Centred Benefit-Risk Project Report, in A framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of newmedical technology. 2015."},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v2.22761"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2578-7"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26921"},{"key":"ref020","doi-asserted-by":"crossref","unstructured":"CookNS, CaveJ, HoltorfA-P Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs. Frontiers in Medicine. 2019:82.","DOI":"10.3389\/fmed.2019.00082"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.09.015"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.07.013"},{"key":"ref023","first-page":"259","volume":"52","author":"Stratford PW","year":"2001","journal-title":"Physiother Can"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.3138\/ptc.2013-45"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007013"},{"key":"ref026","unstructured":"MulK, WijayantoF, LoonenTG, GrootP, VincentenSC, KnuijtS et al. Development and validation of the patientreported \u201cFacial Function Scale\u201d for facioscapulohumeral muscular dystrophy. Disability and Rehabilitation. 2022:1-6."},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2014.09.014"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1177\/2168479017720247"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0718-x"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2630-4"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-7625.2012.00795.x"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1007\/s12687-021-00524-5"},{"key":"ref033","first-page":"161","volume":"6","author":"Lochm\u00fcller H","year":"2019","journal-title":"Report from the 235th ENMC workshop: Milan, Italy, January 19-20, Journal of Neuromuscular Diseases"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1103-8"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172532"},{"key":"ref036","doi-asserted-by":"crossref","unstructured":"WangRT, FadlonCAS, UlmJW, JankovicI, EskinA, LuA et al. Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Currents. 2014;6.","DOI":"10.1371\/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36110"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2011.10.022"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01026-w"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1007\/s12687-021-00520-9"},{"key":"ref041","unstructured":"EURO-NMD. FSHD European Trial Network 2021 [cited 30\/09\/2022];Available from: https:\/\/ern-euro-nmd.eu\/fshdeuropean-trial-network\/."},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.1080\/09638288.2016.1212109"},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001008"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008393"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.004"},{"key":"ref046","doi-asserted-by":"crossref","unstructured":"PetersonIS, MazzellaAJ, BelterLT, CurryMA, CruzRE, JareckiJ The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices. Neurology and Therapy. 2022:1-15.","DOI":"10.1007\/s40120-022-00360-w"},{"key":"ref047","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy364"},{"key":"ref048","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200757"},{"key":"ref049","doi-asserted-by":"crossref","unstructured":"MonforteM, AttarianS, VissingJ, Diaz-ManeraJ, TascaG 265th ENMC international workshop: Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): Relevance for clinical trials. 22\u201324 April 2022, Hoofddorp, The Netherlands. Neuromuscular Disorders. 2022.","DOI":"10.1016\/j.nmd.2022.10.005"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-230171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-230171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-230171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:38Z","timestamp":1777506758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-230171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,5]]}},"alternative-id":["10.3233\/JND-230171"],"URL":"https:\/\/doi.org\/10.3233\/jnd-230171","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}